CGG-repeat dynamics and FMR1 gene silencing in fragile X syndrome stem cells and stem cell-derived neurons.
Yifan Zhou, Daman Kumari, Nicholas Sciascia and 1 others
PMID 27713816WHAT IT FOUND
Fragile X stem cells showed CGG repeat contractions but no large expansions.
Unmethylated alleles below 400 repeats stayed unmethylated through culture and neuronal differentiation. No patient outcome was tested.
Key findings
01The premutation iPSC lines HT14 and SC120 showed CGG repeat contractions over passages but no expansions.
02The WCMC37 full mutation embryonic stem cell line had about 100% FMR1 promoter methylation and about 5% of normal FMR1 mRNA, and sublines with repeats below 400 became unmethylated or partially unmethylated.
03Neurons differentiated from the unmethylated 37D line, a WCMC37-derived full mutation line, did not show new FMR1 methylation or silencing.
STILL TO COME
How it was doneWhat they found
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
This work used stem cell lines and cultured neurons, not patients, so it cannot show what happens in a person with fragile X syndrome. The findings come from a small number of cell lines and sublines, so the repeat-size threshold may not apply to every fragile X carrier. The authors note it can be hard to tell whether silenced alleles become common because differentiation causes silencing or because silenced cells grow better. No clinical outcomes such as movement, learning, speech, or daily function were measured.
Declared interests
The paper lists funding from the National Institute of Diabetes and Digestive and Kidney Diseases and the NIH Center for Regenerative Medicine. No other conflict declaration is given in the supplied text.
The easy way to misread this
Do not read this as evidence that any therapy prevents or reverses fragile X gene silencing. It tested stem cell lines, not patients.